JP2011515349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515349A5 JP2011515349A5 JP2010550897A JP2010550897A JP2011515349A5 JP 2011515349 A5 JP2011515349 A5 JP 2011515349A5 JP 2010550897 A JP2010550897 A JP 2010550897A JP 2010550897 A JP2010550897 A JP 2010550897A JP 2011515349 A5 JP2011515349 A5 JP 2011515349A5
- Authority
- JP
- Japan
- Prior art keywords
- uric acid
- pharmaceutical composition
- composition according
- dimethylbenzyloxy
- methylphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 12
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 12
- 229940116269 uric acid Drugs 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- IYOFVSUBBMQUQM-UHFFFAOYSA-N 2-[3-[(2,6-dimethylphenyl)methoxy]-4-methylphenyl]acetic acid Chemical compound CC1=CC=C(CC(O)=O)C=C1OCC1=C(C)C=CC=C1C IYOFVSUBBMQUQM-UHFFFAOYSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000029142 excretion Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 201000001431 Hyperuricemia Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 108010092464 Urate Oxidase Proteins 0.000 claims 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3629408P | 2008-03-13 | 2008-03-13 | |
| US61/036,294 | 2008-03-13 | ||
| PCT/US2009/037128 WO2009151695A1 (en) | 2008-03-13 | 2009-03-13 | Compounds and method for reducing uric acid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012035313A Division JP5547222B2 (ja) | 2008-03-13 | 2012-02-21 | 尿酸を減少させる化合物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011515349A JP2011515349A (ja) | 2011-05-19 |
| JP2011515349A5 true JP2011515349A5 (enExample) | 2012-04-12 |
| JP5339545B2 JP5339545B2 (ja) | 2013-11-13 |
Family
ID=41417026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550897A Expired - Fee Related JP5339545B2 (ja) | 2008-03-13 | 2009-03-13 | 尿酸を減少させる化合物及び方法 |
| JP2012035313A Expired - Fee Related JP5547222B2 (ja) | 2008-03-13 | 2012-02-21 | 尿酸を減少させる化合物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012035313A Expired - Fee Related JP5547222B2 (ja) | 2008-03-13 | 2012-02-21 | 尿酸を減少させる化合物及び方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8829058B2 (enExample) |
| EP (2) | EP2268141B1 (enExample) |
| JP (2) | JP5339545B2 (enExample) |
| KR (2) | KR101677945B1 (enExample) |
| CN (2) | CN101969773B (enExample) |
| AU (1) | AU2009258040B8 (enExample) |
| BR (2) | BRPI0924547B1 (enExample) |
| CA (1) | CA2716860C (enExample) |
| DK (1) | DK2268141T3 (enExample) |
| ES (1) | ES2741153T3 (enExample) |
| IL (2) | IL208004A (enExample) |
| MX (2) | MX2010009959A (enExample) |
| NZ (2) | NZ587433A (enExample) |
| RU (2) | RU2501555C2 (enExample) |
| UA (2) | UA103894C2 (enExample) |
| WO (1) | WO2009151695A1 (enExample) |
| ZA (1) | ZA201005872B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2268141T3 (da) | 2008-03-13 | 2019-07-29 | Wellstat Therapeutics Corp | Forbindelse og fremgangsmåde til at reducere urinsyre |
| NZ588374A (en) | 2008-04-30 | 2012-11-30 | Wellstat Therapeutics Corp | Tetrazole compounds for reducing uric acid |
| JP5806221B2 (ja) * | 2009-10-13 | 2015-11-10 | ウェルスタット セラピューティクス コーポレイション | 尿酸を減少させる３−置換化合物 |
| WO2012033720A1 (en) | 2010-09-08 | 2012-03-15 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
| EP2669270B1 (en) | 2011-01-28 | 2018-01-03 | Sato Pharmaceutical Co., Ltd. | Indole-related compounds as urat1 inhibitors |
| US20140142185A1 (en) * | 2011-03-14 | 2014-05-22 | Shalini Sharma | 3-Benzyloxyphenyloxoacetic Acid Compounds for Reducing Uric Acid |
| US9060987B2 (en) | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
| US9023856B2 (en) | 2011-11-04 | 2015-05-05 | Cymabay Therapeutics, Inc. | Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent |
| AU2013245675B2 (en) * | 2012-04-13 | 2017-02-09 | Cymabay Therapeutics, Inc. | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
| DK2878594T3 (en) | 2012-07-27 | 2019-02-04 | Sato Pharma | DIFLUOROMETHYLENE COMPOUND |
| US11000492B2 (en) | 2015-11-13 | 2021-05-11 | The Trustees Of Columbia University In The City Of New York | Fluorenone compound for the treatment of gout |
| US12057228B1 (en) | 2015-12-30 | 2024-08-06 | Cerner Innovation, Inc. | Predicting newly incident chronic kidney disease |
| CN106190954B (zh) * | 2016-07-25 | 2019-12-10 | 华南理工大学 | 一种高尿酸血症肝细胞模型及其构建方法 |
| CN106190953B (zh) * | 2016-07-25 | 2019-12-10 | 华南理工大学 | 一种高尿酸血症细胞模型及其构建方法与在降尿酸功效评价方面的应用 |
| KR101988867B1 (ko) | 2017-07-25 | 2019-06-13 | 광주과학기술원 | 금 나노입자를 이용한 요산 분해용 조성물 |
| WO2019066469A1 (ko) * | 2017-09-27 | 2019-04-04 | 경북대학교 산학협력단 | 페북소스타트 또는 토피록소스타트의 암 전이의 예방 및 치료제로서의 용도 |
| WO2021194294A1 (ko) * | 2020-03-27 | 2021-09-30 | 가톨릭대학교 산학협력단 | 자가면역질환 평가 아바타 모델 플랫폼 |
| KR102836208B1 (ko) * | 2020-03-27 | 2025-07-18 | 가톨릭대학교 산학협력단 | 통풍 동반 관절염 모델 평가 플랫폼 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2572512B1 (fr) | 1984-10-25 | 1987-09-25 | Luchaire Sa | Dispositif, adaptable sur engins ou munitions, tels que projectiles d'artillerie, destine a reduire leur trainee de culot |
| EP0279630B1 (en) | 1987-02-16 | 1993-10-13 | Konica Corporation | Developer for light-sensitive lithographic printing plate capable of processing commonly the negative-type and the positive type and developer composition for light-sensitive material |
| US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| GB9315595D0 (en) | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
| AU4953796A (en) | 1995-03-15 | 1996-10-02 | Sanyko Company, Limited | Dipeptide compounds having ahpba structure |
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| WO2001036351A2 (en) * | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| IL159320A0 (en) | 2001-06-12 | 2004-06-01 | Wellstat Therapeutics Corp | Compounds for the treatment of metabolic disorders |
| JP2006507303A (ja) * | 2002-11-01 | 2006-03-02 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の処置のための化合物 |
| KR101106631B1 (ko) * | 2003-02-13 | 2012-01-20 | 웰스태트 테러퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| BRPI0409469B1 (pt) * | 2003-04-15 | 2016-04-26 | Wellstat Therapeutics Corp | compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos |
| JP4837557B2 (ja) | 2003-04-30 | 2011-12-14 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の処置のための化合物 |
| US20040242491A1 (en) * | 2003-05-30 | 2004-12-02 | Lytone Enterpprise Inc. | Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide |
| US7323480B2 (en) * | 2004-05-25 | 2008-01-29 | Metabolex, Inc. | Substituted triazoles as modulators of PPAR and methods of their preparation |
| US7622491B2 (en) * | 2004-08-13 | 2009-11-24 | Metabolex Inc. | Modulators of PPAR and methods of their preparation |
| US7494537B2 (en) * | 2004-11-15 | 2009-02-24 | The Pilot Ink Co., Ltd. | Thermochromic coloring color-memory composition and thermochromic coloring color-memory microcapsule pigment containing the same |
| AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| UA95613C2 (ru) * | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
| KR20080086523A (ko) | 2006-01-25 | 2008-09-25 | 웰스태트 테러퓨틱스 코포레이션 | 물질대사 장애의 치료용 화합물 |
| US20070197512A1 (en) * | 2006-01-27 | 2007-08-23 | Japan Tobacco Inc. | Carboxylic Acid Compounds and Use Thereof |
| US7838556B2 (en) * | 2006-02-21 | 2010-11-23 | University Of Maryland, Baltimore | Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands |
| JP2009532372A (ja) * | 2006-03-31 | 2009-09-10 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の併用治療 |
| EP2026659A4 (en) | 2006-06-09 | 2010-06-30 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER |
| NZ574664A (en) * | 2006-08-17 | 2012-06-29 | Wellstat Therapeutics Corp | Combination treatment for metabolic disorders comprising an incretin mimetic such as exendin or a dppv iv inhibitor |
| EP2240024A4 (en) | 2008-01-15 | 2014-05-21 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| DK2268141T3 (da) | 2008-03-13 | 2019-07-29 | Wellstat Therapeutics Corp | Forbindelse og fremgangsmåde til at reducere urinsyre |
| NZ588374A (en) | 2008-04-30 | 2012-11-30 | Wellstat Therapeutics Corp | Tetrazole compounds for reducing uric acid |
| WO2012033720A1 (en) | 2010-09-08 | 2012-03-15 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
-
2009
- 2009-03-13 DK DK09762990.1T patent/DK2268141T3/da active
- 2009-03-13 UA UAA201012059A patent/UA103894C2/ru unknown
- 2009-03-13 BR BRPI0924547-2A patent/BRPI0924547B1/pt not_active IP Right Cessation
- 2009-03-13 AU AU2009258040A patent/AU2009258040B8/en not_active Ceased
- 2009-03-13 UA UAA201202932A patent/UA109638C2/ru unknown
- 2009-03-13 KR KR1020147023462A patent/KR101677945B1/ko not_active Expired - Fee Related
- 2009-03-13 US US12/920,555 patent/US8829058B2/en active Active
- 2009-03-13 MX MX2010009959A patent/MX2010009959A/es active IP Right Grant
- 2009-03-13 RU RU2012110592/15A patent/RU2501555C2/ru active
- 2009-03-13 JP JP2010550897A patent/JP5339545B2/ja not_active Expired - Fee Related
- 2009-03-13 CA CA2716860A patent/CA2716860C/en not_active Expired - Fee Related
- 2009-03-13 EP EP09762990.1A patent/EP2268141B1/en active Active
- 2009-03-13 NZ NZ587433A patent/NZ587433A/xx not_active IP Right Cessation
- 2009-03-13 WO PCT/US2009/037128 patent/WO2009151695A1/en not_active Ceased
- 2009-03-13 KR KR1020107021875A patent/KR101677944B1/ko not_active Expired - Fee Related
- 2009-03-13 CN CN200980108707.1A patent/CN101969773B/zh not_active Expired - Fee Related
- 2009-03-13 CN CN201210548148.XA patent/CN102976928B/zh not_active Expired - Fee Related
- 2009-03-13 BR BRPI0909299-4A patent/BRPI0909299B1/pt not_active IP Right Cessation
- 2009-03-13 EP EP19158335.0A patent/EP3517109A1/en active Pending
- 2009-03-13 ES ES09762990T patent/ES2741153T3/es active Active
- 2009-03-13 MX MX2013011790A patent/MX342806B/es unknown
- 2009-03-13 RU RU2010141823/15A patent/RU2501554C2/ru active
- 2009-03-13 NZ NZ60232109A patent/NZ602321A/xx not_active IP Right Cessation
-
2010
- 2010-08-17 ZA ZA2010/05872A patent/ZA201005872B/en unknown
- 2010-09-06 IL IL208004A patent/IL208004A/en active IP Right Grant
-
2012
- 2012-02-21 JP JP2012035313A patent/JP5547222B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-09 US US13/890,789 patent/US9115072B2/en active Active - Reinstated
-
2016
- 2016-08-07 IL IL247136A patent/IL247136B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011515349A5 (enExample) | ||
| JP2011519865A5 (enExample) | ||
| KR101567885B1 (ko) | 고요산혈증 및 고요산혈증 관련 대사 장애를 치료하기 위한 방법 및 조성물 | |
| RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
| US20070105894A1 (en) | Combination of at least two compounds selected from an AT1-receptorantagonist or an ACE inhibitor or a HMG-Co-A reductase inhibitor | |
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| JP2010518122A5 (enExample) | ||
| RU2010148762A (ru) | Тетразольные соединения для снижения концентрации мочевой кислоты | |
| JP2012520866A5 (enExample) | ||
| JP2016164165A5 (enExample) | ||
| ES2376493T3 (es) | Procedimiento para reducir o aliviar la inflamación en el tubo digestivo. | |
| ES2449340T3 (es) | Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales | |
| AU2020201980A1 (en) | Combination of FXR agonists | |
| JP2014532758A5 (enExample) | ||
| MX357507B (es) | Metodos para tratar hiperucemia en pacientes con gota utilizando halofenato o acido halofenico y un segundo agente de reduccion de urato. | |
| EA200601286A1 (ru) | Фармацевтические композиции, содержащие ингибитор протонового насоса и прокинетический агент | |
| RU2012107483A (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
| JPWO2008099907A1 (ja) | 尿排出障害治療剤 | |
| JP7658909B2 (ja) | 筋ジストロフィー治療薬 | |
| TW201215389A (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
| ES2779724T3 (es) | Prevención y/o agente terapéutico para la fibromialgia | |
| WO2014117117A1 (en) | Chronic nsaid treatment for fuchs endothelial corneal dystrophy | |
| RU2007129567A (ru) | Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии | |
| JP2005519918A5 (enExample) | ||
| JP2008525314A5 (enExample) |